The Agilent Technologies SureSelect Platform for Target Enrichment

Similar documents
The Agilent Technologies SureSelect Platform for Target Enrichment

Cancer Genetics Solutions

Target Enrichment Strategies for Next Generation Sequencing

Gene Regulation Solutions. Microarrays and Next-Generation Sequencing

Next Generation Sequencing. Target Enrichment

Welcome to the NGS webinar series

A Genomics (R)evolution: Harnessing the Power of Single Cells

Targeted Sequencing Using Droplet-Based Microfluidics. Keith Brown Director, Sales

ACCEL-NGS 2S DNA LIBRARY KITS

QIAGEN s NGS Solutions for Biomarkers NGS & Bioinformatics team QIAGEN (Suzhou) Translational Medicine Co.,Ltd

Next-Generation Sequencing. Technologies

March 20-23, 2010 Sacramento, CA

Bioinformatics Advice on Experimental Design

High Cross-Platform Genotyping Concordance of Axiom High-Density Microarrays and Eureka Low-Density Targeted NGS Assays

Complete Sample to Analysis Solutions for DNA Methylation Discovery using Next Generation Sequencing

SureSelect Clinical Research Exome V2 Definitive Answers Where it Matters Most

IMGM Laboratories GmbH. Sales Manager

Gene Expression Profiling and Validation Using Agilent SurePrint G3 Gene Expression Arrays

Incorporating Molecular ID Technology. Accel-NGS 2S MID Indexing Kits

Ion S5 and Ion S5 XL Systems

High-Resolution Oligonucleotide- Based acgh Analysis of Single Cells in Under 24 Hours

Gene Expression Technology

Single Nucleotide Variant Analysis. H3ABioNet May 14, 2014

High-yield, Scalable Library Preparation with the NEBNext Ultra II FS DNA Library Prep Kit

NGS 101 Panel Design and Quality. Adam Hauge Development Manager University of Minnesota Genomics Center

Digital DNA/RNA sequencing enables highly accurate and sensitive biomarker detection and quantification

SMARTer Ultra Low RNA Kit for Illumina Sequencing Two powerful technologies combine to enable sequencing with ultra-low levels of RNA

Optimizing FFPE DNA preparation for use in SureSelect XT2

QIAGEN Whole Genome Amplification REPLI-g Eliminating Sample Limitations, Potential Use for Reference Material

Ion S5 and Ion S5 XL Systems

Impact of gdna Integrity on the Outcome of DNA Methylation Studies

Targeted resequencing

Expression Array System

DNA. bioinformatics. epigenetics methylation structural variation. custom. assembly. gene. tumor-normal. mendelian. BS-seq. prediction.

Getting high-quality cytogenetic data is a SNP.

Complementary Technologies for Precision Genetic Analysis

Gene Expression on the Fluidigm BioMark HD

Scaling Up NGS Sample Preparation: Automation and Lab Preparation. Alicia Burt Sr. Product Manager

Lecture #1. Introduction to microarray technology

Application Note. Genomics. Abstract. Authors. Kirill Gromadski Ruediger Salowsky Susanne Glueck Agilent Technologies Waldbronn, Germany

From Variants to Pathways: Agilent GeneSpring GX s Variant Analysis Workflow

Single Cell Genomics

Detecting Rare Genomic Copies or Events

NGS: Digital RNAseq & Library Prep Seminar. Next-Generation Sequencing Lunch & Learn

Lab methods: Exome / Genome. Ewart de Bruijn

Agilent Genomics Software Future Directions

Jenny Gu, PhD Strategic Business Development Manager, PacBio

Axygen AxyPrep Magnetic Bead Purification Kits. A Corning Brand

The first and only fully-integrated microarray instrument for hands-free array processing

LATE-PCR. Linear-After-The-Exponential

PrimePCR Assay Validation Report

PrimePCR Assay Validation Report

Agilent Genomic Workbench 7.0

SNP GENOTYPING WITH iplex REAGENTS AND THE MASSARRAY SYSTEM

Whole Transcriptome Analysis of Illumina RNA- Seq Data. Ryan Peters Field Application Specialist

Implementation of Automated Sample Quality Control in Whole Exome Sequencing

Research school methods seminar Genomics and Transcriptomics

Introduction to Next Generation Sequencing (NGS) Andrew Parrish Exeter, 2 nd November 2017

Introduction to the UCSC genome browser

Product selection guide Ion GeneStudio S5 Series

Course Overview: Mutation Detection Using Massively Parallel Sequencing

RIPTIDE HIGH THROUGHPUT RAPID LIBRARY PREP (HT-RLP)

High-throughput profiling, confirmation, and screening in a mid-density format. The QuantStudio 12K Flex Real-Time PCR System

Accessible answers. Targeted sequencing: accelerating and amplifying answers for oncology research

Introduction to Bioinformatics and Gene Expression Technologies

PrimePCR Assay Validation Report

Next-Generation Sequencing Services à la carte

Next Generation Sequencing: Data analysis for genetic profiling

PrimePCR Assay Validation Report

Exploring new frontiers with next-generation sequencing

Outline. General principles of clonal sequencing Analysis principles Applications CNV analysis Genome architecture

PCR SYSTEMS. a new era in high-productivity qpcr. Applied Biosystems ViiA 7 Real-Time PCR System

PrimePCR Assay Validation Report

2100 Bioanalyzer. Overview & News. Ralph Beneke Dec 2010

Identification of the Photoreceptor Transcriptional Co-Repressor SAMD11 as Novel Cause of. Autosomal Recessive Retinitis Pigmentosa

Introductory Next Gen Workshop

Targeted Sequencing of Leukemia-Associated Genes Using 454 Sequencing Systems

Targeted Sequencing in the NBS Laboratory

Release Notes for Genomes Processed Using Complete Genomics Software

Getting the Most from Your DNA Analysis from Purification to Downstream Analysis. Eric B. Vincent, Ph.D. February 2013

Multiplex Assay Design

CS273B: Deep Learning in Genomics and Biomedicine. Recitation 1 30/9/2016

Oncomine cfdna Assays Part III: Variant Analysis

Fundamentals of Next-Generation Sequencing: Technologies and Applications

Molecular Markers CRITFC Genetics Workshop December 9, 2014

Enhancers mutations that make the original mutant phenotype more extreme. Suppressors mutations that make the original mutant phenotype less extreme

DNA Microarray Technology

Whole genome sequencing in drug discovery research: a one fits all solution?

Sequencing technologies. Jose Blanca COMAV institute bioinf.comav.upv.es

Third Generation Sequencing

Product selection guide Ion S5 and Ion S5 XL Systems

Nature Methods: doi: /nmeth Supplementary Figure 1

SOLiD Total RNA-Seq Kit SOLiD RNA Barcoding Kit

Corporate Medical Policy

Validation Study of FUJIFILM QuickGene System for Affymetrix GeneChip

IPA Advanced Training Course

Variant calling in NGS experiments

Custom TaqMan Assays DESIGN AND ORDERING GUIDE. For SNP Genotyping and Gene Expression Assays. Publication Number Revision G

Amplicon Sequencing Template Preparation

Detecting copy-neutral LOH in cancer using Agilent SurePrint G3 Cancer CGH+SNP Microarrays

Transcription:

The Agilent Technologies SureSelect Platform for Target Enrichment Focus your next-gen sequencing on DNA that matters Kimberly Troutman Field Applications Scientist January 27 th, 2011

Agenda 1 Introduction: SureSelect TM 2 Exome Approach for Genetic Diseases 3 Complex Diseases 4 Custom Biomarker Discovery and Profiling 5 Targeted RNA Sequencing 6 Kinome Kit 7 New SureSelect Products Page 2

Target Enrichment: A Highly Enabling Process What? Also referred to as genome partitioning, targeted re-sequencing, DNA capture Captures genomic material of interest for next generation sequencer (i.e. Illumina, SOLiD, 454 etc ) gdna Why? Sequence your regions of interest! Enables focus on a subset of the genome Saves both time and money for downstream sequencing Enriched library Identify homozygous and heterozygous variants in targets relative to the reference genome Page 3

Agilent s SureSelect Platform: Two Options SureSelect Target Enrichment System* Developed in collaboration with the Broad Institute Dr. Chad Nusbaum et al. SureSelect DNA Capture Array Developed in collaboration with Cold Spring Harbor Dr. Greg Hannon et al. 3 µg gdna Agilent 60-mer Array 244k & 1M features 1-5 µg gdna (with WGA) or 20 µg gdna (unamplified) *Flagship Method Released February 2009 Released July 2009 Page 4

Baits crna probes Long (120 bases) Biotin labeled Illumina GAII x Illumina HiSeq SOLiD 3 SOLiD 4 5500 GS FLX & GS JR

SureSelect Target Enrichment Kit Choices Product Target amount (Mb) Reactions/kit Product Definition Human X- demo Human All Exon v1 Human All Exon Plus Human All Exon v2 Human All Exon 50Mb 3.05 5 Human X-chr Exons 38 5-10,000 38-50 plus up to 6.8 of custom content 5-10,000 44 5-10,000 50 5-10,000 Catalog content from CCDS 2008 plus >1000 ncrna Add custom content to All Exon catalog content CCDS Sept. 2009 Plus additional RefSeq GENCODE content Most comprehensive coverage Multiplexable Kinome 3.2 5-10,000 All kinases Indexed custom content <0.2 0.2-0.49 0.5-1.49 1.5-2.9 3-6.8 10-5,000 Custom offering -Illumina (12 indexes) -SOLiD (16 barcodes)

SureSelect Kits Multiplexing Capability Target Enrichment Size Ranges Illumina AB SOLiD GA HiSeq 2000 Octet Quadrant Flow Cell Full Run <200 Kb targets 12 12 16 16 16 16 200 Kb - 499 Kb targets 12 12 16 16 16 16 500 Kb - 1.49 Mb targets 12 12 5 10 16 16 1.5 Mb - 2.99 Mb targets 12 12 3 7 16 16 3.0 Mb - 6.0 Mb targets 8 12 2 3 16 16 Human All Exon 38 Mb 1 4 0 1 3 7 Human All Exon 50 Mb 1 3 0 0 3 5

XT

Agilent SureSelect XT Kits gdna kit + Library Prep kit + SureSelect Reagents = SureSelect XT Kit SureSelect XT Kit Coupled with an optimized gdna prep and library prep kit, allows the use one kit for the entire, sample-prep-to-sequencing target enrichment workflow Kit composition gdna Isolation Lysis buffer and enzymes required for isolation Library prep Buffers, reagents, enzymes and indexes needed for prep SureSelect Target Enrichment Kit Hybridization buffers and baits All kits are available in the XT format- catalog kits and custom content SureSelect XT All Exome & SureSelect XT All Exome Plus SureSelect XT Human Kinome & SureSelect XT Human X Chromosome SureSelect XT Custom from < 200 Kb to > 6.8 Mb (up to 34 Mb in Spring 2011) Illumina GAIIx and HiSeq 2000 (Protocol v1.0 Nov 2010) SOLiD 3 / 4 and 5500 (Available soon)

SureSelect XT complete sample to sequencer solutions for your target enrichment needs Genomic DNA prep Manual Procedure for small number of samples Library prep (GA, SOLiD) Bioanalyzer, qpcr quant Sequencer Page 11

Agenda 1 Introduction: SureSelect TM 2 Exome Approach for Genetic Diseases 3 Complex Diseases 4 Custom Biomarker Discovery and Profiling 5 Targeted RNA Sequencing 6 Kinome Kit 7 New SureSelect Products Page 12

Exon Capture is a Powerful Tool to Study Mendelian Diseases Mendelian diseases are caused by coding mutations (with some exceptions) Exons are only ~1-1.4 % of human genome (30-50Mb) Primarily protein coding regions Advantages: Much less sequencing ~5% of WGS, so up to 20x more samples All Exons on X chromosomes 7674 exons 3 Mb Why coding? More interpretable Easier to follow up Especially adapted to study of Mendelian diseases CCDS exons v1 CCDS + RefSeq 38 Mb v2 (Broad) GENCODE 50 Mb (Sanger) Includes ncrna Page 13

Applications to Mendelian disorders and many more to come Page 16

SureSelect Human All Exon Kits All Exon v1 All Exon v2 All Exon50 Mb CCDS Sept. 2008 CCDS Sept. 2008 + additional RefSeq content including CCDS Sept. 2009 exons GENCODE and Sanger (includes CCDS and Broad defined v2 content as well) CCDS (Nov. 2010) 89.6% 98.2% 99.5% CNV (Mar. 2010) 23.98% 27.49% 30.62% Ensembl (Aug. 2010) 79.9% 90.9% 96.2% mirna (mirbase 14) 90.0% 90.0% 92.8% GenBank (6/16/2010) 75.96% 89.07% 90.74% RefSeq Genes (Nov. 2010) 85.0% 96.9% 99.0% RefSeq Transcripts (6/16/2010) 88.85% 95.07% 97.50% Target Size 38Mb 44Mb 50Mb Developed with Broad Broad Sanger Human All Exon kits can be customized (PLUS) with up to 6.8 Mb additional custom content Human All Exon kits can be multiplexed on SOLiD4 and HiSeq2000 Page 17

Human All Exon 50Mb 2x76 bp, 50-60M HQ Reads 100% 90% 80% 70% 60% 50% 40% 76.32% 85.07% 96.65% 87.93% 77.46% The most comprehensive Human All Exon content available 38 Mb design = a subset of 50 Mb Sequencing capacity: 0.5-1 sample / lane GAIIx 1-3 samples / lane HiSeq 5-10 samples /full slide SOLiD4 30% 20% 10% Chemistry recommended: PE 2x76 bp Illumina v4 PE 50+25 SOLiD 0% % on target +/- 100bp Uniformity (3/4 mean with upper tail): % bases with 1x coverage % bases with 10x coverage % bases with 20x coverage Multiplexing: Illumina SOLiD Page 18

Comparison of SNP Calls with HapMap Genotype Sensitivity vs. HapMap Genotype Concordance vs. HapMap 100% 99.1% 99.2% 98.4% 98.0% 100% 99.8% 99.4% 99.7% 99.3% 98.2% 98.5% 98.1% 98.3% 95% 95.7% 94.9% 95% 90% 90% 85% 85% 80% 80% 75% 75% 70% Human All Exon v2 Human All Exon 50Mb 70% Human All Exon v2 Human All Exon 50Mb GT is REF GT is variant HET GT is variant HOM GT is REF GT is variant HET GT is variant HOM OVERALL Page 19

All Exon Plus Is the Human All Exon Kit not hitting all of your regions of interest? Enter Your Custom Regions in earray CCDS exons >1000 ncrnas 38 Mb All Exon Library + Your Custom Library Your regions of interest (6.8 Mb) Page 20

22394 23224 24337 21976 26352 No. SNPs 4480 5173 5528 5816 6182 Human All Exon Plus Performance 1 tube capture, 1 lane seq. at 2x76 bp on GAIIx = ~2 Gb SNP Analysis vs. HapMap SNP Analysis vs. dbsnp 100% 90% 80% 35000 30000 70% 25000 60% 50% 20000 40% 15000 30% 10000 20% 10% 5000 0% Exome + 0.87 Mb Exome + 1.7 Mb Exome + 3.4 Mb Exome + 6.8 Mb Exome Control 0 Exome + 0.87 Mb Exome + 1.7 Mb Exome + 3.4 Mb Exome + 6.8 Mb Exome Control Sensitivity Concordance Concordant Novel Mismatched Page 21

Agenda 1 Introduction: SureSelect TM 2 Exome Approach for Genetic Diseases 3 Complex Diseases 4 Custom Biomarker Discovery and Profiling 5 Targeted RNA Sequencing 6 Kinome Kit 7 New SureSelect Products Page 22

Page 23 Beyond Mendelian Diseases: Complex diseases

Beyond Mendelian Diseases: Complex diseases 25bp deletion 7bp deletion 10bp deletion 11bp deletion Page 24

Agenda 1 Introduction: SureSelect TM 2 Exome Approach for Genetic Diseases 3 Complex Diseases 4 Custom Biomarker Discovery and Profiling 5 Targeted RNA Sequencing 6 Kinome Kit 7 New SureSelect Products Page 25

Other Applications of Targeted Re-Sequencing Capture any custom genomic regions (introns, exons, UTRs, regulatory, etc.) Ideal for biomarkers discovery and profiling (e.g. cancer) Ideal for custom SNP follow-up Ideal for characterization of large sample cohorts Key enabling features: High throughput 12 Illumina indexes / up to 96 samples per run 16 SOLiD barcodes / up to 128 samples per run Only pay what you capture, scalable from 0.2 to 6.9 Mb (sweet spot for 3 rd Gen Seq) <0.2 Mb 0.2 0.5 Mb 0.5 1.5 Mb 1.5 3 Mb 3 6.9 Mb Very reproducible, excellent allelic balance for accurate heterozygote calls Custom and catalog content (kinome) Automation (library prep and capture) Page 26

Target Enrichment Design Application in earray earray is a tool to design and order custom microarrays, qpcr primers and SureSelect products (and it is free!!) earray is divided into Application Spaces Allows for application specific functionality Target Enrichment application space features: Create custom baits and bait libraries Search existing designs/baits Catalog and custom Upload custom bait designs Download design files Share designs Get quotes Page 27

Customize your SureSelect TM Kit Create your own design or add extra custom sequence to a catalog design up to 6.8Mb earray Webportal Customer A Gene ID 1 Gene ID 2 Gene ID 3 Bait design Bait design Bait design Baits #1 Baits #2 Baits #3 Library design Kit size Virtual bait library Up to 55,000 unique baits Quote Order library DNA bait library RNA bait library Customer B https://earray.chem.agilent.com Kit Assemble kit Ship Kit to Customer Page 28

Sequence Any Genome- earray XD

Page 30 The Power of Smaller SureSelect Panels

Inherited loss-of-function mutations in the tumor suppressor genes BRCA1, BRCA2, and multiple other genes predispose to high risks of breast and/or ovarian cancer. Cancerassociated inherited mutations in these genes are collectively quite common, but individually rare or even private. To determine whether massively parallel, next-generation sequencing would enable accurate, thorough, and cost-effective identification of inherited mutations for breast and ovarian cancer, we developed a genomic assay to capture [with Agilent s custom SureSelect], sequence, and detect all mutations in 21 genes, including BRCA1 and BRCA2, with inherited mutations that predispose to breast or ovarian cancer. There were zero false-positive calls of nonsense mutations, frameshift mutations, or genomic rearrangements for any gene in any test sample. This approach enables widespread genetic testing and personalized risk assessment for breast and ovarian cancer. Page 31

Deletion up to 19bp Excellent allelic balance Page 32

Efficient Capture of 5 bp Deletion on Chr X: Menke s Syndrome SureSelect Target Enrichment Kit Efficiently Captures 5 bp Mutant Readout on Illumina GA hg18_chrx_77131408_77131467_+ : Wild type Bait Design CTATTGTTTATCAACCTCATCTTATCTCAGTAGAGGAAATGAAAAAGCAGATTGAAGCT CTATTGTTTATCAACCTCATCTT-----AGTAGAGGAAATGAAAA ATTGTTTATCAACCTCATCTT-----AGTAGAGGAAATGAAAAAG TTGTTTATCAACCTCATCTT-----AGTAGAGGAAATGAAAAAGC GTTTATCAACCTCATCTT-----AGTAGAGGAAATGAAAAAGCAG TATCAACCTCATCTT-----AGTAGAGGAAATGAAAAAGCAGATT ATCAACCTCATCTT-----AGTAGAGGAAATGAAAAAGCAGATTG ATCAACCTCATCTT-----AGTAGAGGAAATGAAAAAGCAGATTG ATCAACCTCATCTT-----AGTAGAGGAAATGAAAAAGCAGATTG CAACCTCATCTT-----AGTAGAGGAAATGAAAAAGCAGATTGAA CCTCATCTT-----AGTAGAGGAAATGAAAAAGCAGATTGAAGCT Page 36

Agenda 1 Introduction: SureSelect TM 2 Exome Approach for Genetic Diseases 3 Complex Diseases 4 Custom Biomarker Discovery and Profiling 5 Targeted RNA Sequencing 6 Kinome Kit 7 New SureSelect Products Page 37

SureSelect TM RNA Target Enrichment FIRST IN CLASS First RNA Capture product on the market Custom and catalog kits Design kits from 200Kb to 3.4Mb using RNA Target Enrichment space on earray portal (PN G7581-G7585) RNA Capture Kinome Kit (catalog) containing same content as current SureSelect Kit (PN G7580)

SureSelect RNA Enrichment Protocol Start with 0.1-0.5ug RNA Similar process to DNA Target enrichment Except that it is a cdna NGS library Protocol time ~ 3-4 days Protocols available Illumina and SOLiD Individual or multiplexed samples

Agenda 1 Introduction: SureSelect TM 2 Exome Approach for Genetic Diseases 3 Complex Diseases 4 Custom Biomarker Discovery and Profiling 5 Targeted RNA Sequencing 6 Kinome Kit 7 New SureSelect Products Page 45

SureSelect kinome Discovery and profiling of biomarkers related to disease and/or drug response Definition of SureSelect Human Kinome Kit: 3.2Mb (incl. UTRs) (Original content defined by Prof. René Bernards NKI) 518 putative kinases 12 PI3K domain-containing genes 13 diglyceride kinases 6 PI3K regulatory components 9 inositol polyphosphate Kinases 9 PIP4/PIP5 Kinases 28 genes frequently mutated in human cancer 19 genes specifically known to be mutated in breast cancer 612 genes total G. Manning et al Science 298 1912 (2002) Slide courtesy of Rene Bernards

Kinome Kit Performance 3-5 samples per GAIIx lane / SOLID quad 100% 80% 60% 40% 20% 0% Kinome Index 1 Reproducible Performance Across Indexes Kinome Index 2 Kinome Index 3 Kinome Index 4 Kinome Index 5 Even Index Representation Across Single Lane 0.98 1.15 1.00 1.15 0.84 Kinome Index 1 Kinome Index 2 Kinome Index 3 Kinome Index 4 Kinome Index 5 Uniform Read Depth Distribution % on target +/- 200bp % Bases 1X Coverage % Bases 10X Coverage % Bases 20X Coverage Page 47

Agenda 1 Introduction: SureSelect TM 2 Exome Approach for Genetic Diseases 3 Complex Diseases 4 Custom Biomarker Discovery and Profiling 5 Targeted RNA Sequencing 6 Kinome Kit 7 New SureSelect Products Page 49

SureSelect + 454 SureSelect support for both 454 FLX and GS Junior sequencers Simplified protocol with a rapid library protocol (<3hrs), the shortest in-solution capture protocol Only 500 ng of starting material required Full SureSelect product line available, custom bait libraries from <200 kb - 6.8 Mb capture size or catalog kit ( Human All Exon, Kinome and X chromosome) Allows for detection of mutations, SNPs, indels, CNVs and fusions/translocations

454 FLX SureSelect Custom Capture: 0.5 Mb 1/4 PicoTiterPlate run, 67 Gb of sequence >95% of capture sequenced at 20X depth or greater DNA Bait and Pond NA10831 00.5Mb_B Avg read length: bases 360.3 Total number of bases mapped: bases 67,157,190 Percentage reads in targeted regions : 57.07% Percentage reads in regions +/- 300bp: 59.35% Average Read Depth: fold 52.7 Percentage of targeted bases covere d by......at least 1 read: 99.34%...at least 5 reads: 98.99%...at least 10 reads: 98.12%...at least 20 reads: 95.42%...at least 30 reads: 88.83%...at least 40 reads: 76.10%

454 FLX SureSelect Custom Capture: 0.5 Mb SNP Detection 343 HapMap SNPs were assayed in replicate samples of NA10831 98% 95% 97% 100% 100% 100%

Cancer Research Gene Fusions Problem: Genomic rearrangement in tyrosine kinase genes Can lead to deregulation of cellular signaling and cancer Identification of novel TK fusions is laborious TKs are attractive therapeutic targets Solution: SureSelect Custom Capture (908 Kb) based on known cancer-derived TK fusions Designed baits to a conserved GXGXXG motif in 90 TKs + ATK and BRAF Regions extended to include preceding exons/introns 454 long-read sequencing SureSelect Custom Capture (908 Kb)

SureSelect XT Mouse All Exon Kit Agilent SureSelect XT Mouse All Exon Kit For SOLiD, Illumina & 454 platforms Available in 5 to 10,000 reactions Designed against UCSC mm9 / NCBI build 37 (July 2007) Exon definition derived from Ensembl + RefSeq Complete Mouse exome coverage 49.6 Mb capture 221,784 exons and 24,306 genes Excellent coverage uniformity, on-target specificity and SNP detection and accuracy

SureSelect XT Mouse All Exon Kit: Illumina GAIIx, single lane 2x76 PE, 5.2 Gb C3H mouse genomic DNA, 49.6 Mb Mouse All Exon Capture On-target reads= 69% 98% of Bases covered at 1x or greater and the average read depth was 54X 84 % of the targeted bases were sequenced at a depth of 20X or greater, enabling highconfidence SNP calling

SureSelect Mouse All Exon Kit SNP Sensitivity & Concordance 99% 99% 98% 95% A) Sensitivity of SNP detection relative to the Perlegen Mouse SNP dataset was very high with the SureSelect XT Mouse All Exon Kit / Illumina GAIIx platform, with 99 percent of reference SNPs detected for the C3H and DBA samples. Variant SNPs were also detected at high rates (99 percent) for both the C3H and DBA samples. B) Of the SNPs detected, concordance with the Perlegen Mouse SNP data set for both the C3H ad DBA samples was 98 percent for the variants and 95 percent overall.

SureSelect XT Catalog Exome Kits Coming soon in 2011 - SureSelect XT Exome Kits for Bovine, Canine, Xenopus, and Zebrafish

Acknowledgements Collaborators: Broad Institute Chad Nussbaum et. al Stacey Gabriel et. al Sheila Fisher et. al Sanger Institute Daniel Turner et.al., NKI Rene Bernards Ian Majewski RIKEN Institute Yoichi Gondo All our early access collaborators (over 20 institutions worldwide)